Vertex Pharmaceuticals Incorporated (VRTX)
Why Vertex Pharmaceuticals (VRTX) Outpaced the Stock Market Today
Vertex Pharmaceuticals (VRTX) closed at $468.09 in the latest trading session, marking a +0.94% move from the prior day.
The Ultimate Biotech Stock to Buy With $500 Right Now
Investing in biotech stocks isn't for everyone because the very nature of their business is fraught with risk. As a result, biotech stocks can be highly volatile.
Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $469.29, indicating a -0.99% shift from the previous trading day.
Why Is Vertex (VRTX) Down 8.6% Since Last Earnings Report?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Got $500? 1 Biotech Stock to Buy and Hold Forever
Got $500? 1 Biotech Stock to Buy and Hold Forever
Buy Signal Flashing For Struggling Biotech
Biotech Vertex Pharmaceuticals (VRTX) has been struggling on the charts over the past few weeks, putting a dent in its now 10% year-to-date gain. The stock's 5.6% post-earnings pop earlier this month has already been erased, and VRTX is now trading at its lowest level since June.
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Stifel 2024 Healthcare Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Stifel 2024 Healthcare Conference November 19, 2024 8:00 AM ET Company Participants Stuart Arbuckle - EVP, COO Conference Call Participants Paul Matteis - Stifel Paul Matteis Great, good morning. It's my pleasure to be moderating this chat with Stuart Arbuckle, COO of Vertex Pharmaceuticals.
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Vertex Pharmaceuticals Incorporated (VRTX) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Guggenheim Inaugural Healthcare Innovation Conference November 12, 2024 9:00 AM ET Company Participants Reshma Kewalramani - President and CEO Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay Good morning, and thank you for joining Guggenheim's Inaugural Healthcare Innovations Conference. I am Debjit, one of the therapeutic analysts, and my privilege to welcome Dr. Reshma Kewalramani, President and CEO of Vertex.
Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity
Regulators are reviewing what could become a multi-billion-dollar drug.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
